AGENDA

25th OCTOBER 2018

Individual arrivals

14.00-16.30 Optional: Guided walking tour (on private expenditure)
Starting and ending point of the tour is the hotel “DoubleTree by Hilton”, Oosterdokstraat 4

17.00-19.00 Steering Committee Meeting (for Steering Committee only)
Venue: Amsterdam Openbare Bibliotheek, 6th floor, OBA Congres, Keizerszaal 6.5
Oosterdokskade 143, 1011 Amsterdam

19.30 Networking dinner at the Restaurant “5&33” in the Art´otel Amsterdam (Martelaarsgracht 5, 1012 Amsterdam)

26th OCTOBER 2018

Venue: Amsterdam Openbare Bibliotheek, 6th floor, OBA Congres, OBA Forum
Oosterdokskade 143, 1011 Amsterdam

09.00-10.00 Welcome & introduction - Petra Reinke - Charité, Germany

10.00-10.20 WP5 - Mechanistic studies - Kathryn Wood / Fadi Issa - University of Oxford, UK
Main results & conclusions & potential impact (10 min.)
Differences to work expected to be carried out (5 min.)
Discussion (5 min.)

10.20-10.40 WP5 - Rat transplant model - Aurélie Moreau - Centre Hospitalier Universitaire de Nantes - France
Main results & conclusions & potential impact (10 min.)
Differences to work expected to be carried out (5 min.)
Discussion (5 min.)

10.40-11.00 Coffee break

11.00-11.30 WP 1A - Study I - Alberto Sanchez Fueyo - King’s College London, UK
Main results & conclusions & potential impact (10 min.)
Differences to work expected to be carried out (5 min.)
What kind of contribution is required for final analysis? (5 min)
Discussion (10 min.)
11.30-11.45 **WP 1B - Study II** - Magali Giral / Sophie Brouard - Centre Hospitalier Universitaire de Nantes - France
Main results & conclusions & potential impact (10 min.)
Discussion (5 min.)

**11.45-12.00 WP 1C - Study III** - Alberto Sanchez Fueyo - King’s College London, UK
(Presentation study of M. Hernandez-Fuentes)
Main results & conclusions & potential impact (10 min.)
Discussion (5 min.)

**12.00-12.30 WP 2 - Study IV “CELLIMIN”** - Josep Grinyó / Oriol Bestard - Institut Català de la Salut, Spain
Main results & conclusions & potential impact (10 min.)
Differences to work expected to be carried out (5 min.)
What kind of contribution is required for final analysis? (5 min)
Discussion (10 min.)

**12.30-13.00 WP 3 - Study V “RIMINI”** - Ondrej Viklicky - Institutu Klinické a Experimentální Medicíny, Czech Republic
Main results & conclusions & potential impact (10 min.)
Differences to work expected to be carried out (5 min.)
What kind of contribution is required for final analysis? (5 min)
Discussion (10 min.)

**13.00-14.00 Lunch**

**14.00-14.30 WP 4 - Biomarker analyses** - Birgit Sawitzki- Charité, Germany
Progress report & first results (10 min.)
What kind of preliminary data will be available for the final report? (5 min.)
What kind of contribution is required for correlation with clinical data? (5 min)
Discussion (10 min.)

**14.30-14.50 WP 4 - Health-economic analyses** - Simon Weber - Cellogic, Germany
Main results & conclusions & potential impact (10 min.)
Differences to work expected to be carried out (5 min.)
Discussion (5 min.)

**14.50-15.10 GenID** - Rosemarie Preyer - GenID, Germany
Main results & conclusions & potential impact (10 min.)
Differences to work expected to be carried out (5 min.)
Discussion (5 min.)
15.10-15.30 Immunotech/Beckman Coulter - Tewfik Miloud - Beckman Coulter Immunotech, France
Main results & conclusions & potential impact (10 min.)
Differences to work expected to be carried out (5 min.)
Discussion (5 min.)

15.30-15.50 Milenia - Ralf Dostatni - Milenia Biotec GmbH, Germany
Main results & conclusions & potential impact (10 min.)
Differences to work expected to be carried out (5 min.)
Discussion (5 min.)

15.50-16.30 Coffee break - Time for EAB + PEC to prepare statements

16.30-16.45 Statements of the Ethics Committee - PEC (10 min.)
Discussion (5 min.)

16.45-17.00 Statements of the External Advisors - EAB (10 min.)
Discussion (5 min.)

17.00-17.30 Recapitulation & discussion - All